Eupry, a leading provider of GxP-compliant temperature and humidity monitoring solutions, has successfully raised $170 million in its latest funding round. This significant investment underscores the growing demand for streamlined temperature compliance processes, especially in industries such as pharmaceuticals, biotech, and logistics. For too long, companies have navigated the complexities of compliance through disjointed systems that are labor-intensive and fraught with potential pitfalls. Eupry's innovative platform integrates temperature monitoring, mapping, and calibration into a single, easy-to-use solution, ensuring that businesses maintain full control over their compliance at all times. The newly acquired funds will be strategically utilized to enhance product development, expand market reach, and accelerate the implementation of Eupry’s digital solutions into more organizations that require strict temperature monitoring to avoid costly product losses and compliance failures. As businesses increasingly recognize the need for cohesive systems to manage temperature compliance, Eupry stands ready to transform how these industries operate, minimizing risks and maximizing efficiency. With this new capital injection, Eupry is poised to solidify its position as a front-runner in the compliance solutions market, providing an essential safety net for businesses under stringent regulatory scrutiny. Now is the perfect time for companies looking to optimize their temperature compliance processes to explore what Eupry has to offer—it’s a game-changing step towards ensuring quality and reliability in their operations.
Revolutionizing Temperature Compliance: Eupry Secures $170 Million in Funding
Get the full Eupry company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Beeline Medicines
Beeline Medicines is a clinical-stage biotechnology company focused on developing and delivering category-leading precision therapies to transform the lives of people living with autoimmune and inflammatory diseases. We are here to chart a new path for patients, rigorously pushing the science forward to deliver therapies that go straight to the drivers of immune dysfunction to define new treatment paradigms. Our portfolio is comprised of therapeutic candidates rooted in validated biology, powered by best-in-class molecular properties, and driven by an efficient clinical development strategy designed for differentiated, lasting impact for patients. Grounded in scientific rigor and driven by purpose, we get to what matters so that people living with immune-mediated diseases can live life fully.
$126.3M Series a
today
Revoraai
Most real estate businesses don’t have a lead problem. They have a conversion problem. Leads come in… But slow replies, missed follow-ups, and unqualified inquiries kill deals. That’s where I help. I build AI-powered systems that: • Instantly respond to new leads • Filter serious buyers • Follow up automatically • Turn conversations into site visits No manual chasing. No missed opportunities. Just a smarter way to convert leads into revenue. If you're in real estate and want to automate your lead flow, let’s connect.
$2.0M Seed
today
LEKO
LEKO Labs is accelerating the global transition to carbon negative construction with building materials powered by AI optimization and robotic manufacturing.
$9.0M Seed
today
Wolf-e Robotics
EU Manufacturer of Smart #UVC Disinfection Devices. Air Purifiers, Applied UV Robotics, Research & Development Platform. Gausium cleaning robots distributor. Democratizing clean air and surfaces in any indoor space. For collabs & enquiries, check our website: www.wolfe.ro.
$54.0K Unknown
today
OxidOS Automotive
OxidOS Automotive is building the next generation of software development tools and Operating Systems for Automotive ECUs, fully written in Rust. The OxidOS platform and Operating System allow automotive manufacturers and integrators to deploy safe and secure software faster, through development, debugging, and certification time reduction.
$54.0K Unknown
today